Annual Report 2023

of the Certified Prostate Cancer Centres

Audit year 2022 / Indicator year 2021

DKG
GERMAN CANCER SOCIETY
Certification

Content

General information

DKG

GERMAN CANCER SOCIETY

Certification

Kennzahl Nr. 4: Active-Surveillance (AS) ....
Kennzahl Nr. 5: Strahlentherapie und hormonablative Therapie bei lokal begrenztem PCa mit hohem Risiko (LL QI 4) .
Kennzahl Nr. 6: Psychoonkologische Betreuung ....
Kennzahl Nr. 7: Beratung Sozialdienst ....
Kennzahl Nr. 8: Studienteilnahme ....
Kennzahl Nr. 9: Anzahl Prostatektomien Zentrum ....
Kennzahl Nr. 10: Erfassung der R1 Resektionen bei pT2 c/pN0 oder Nx M0 ....
Kennzahl Nr. 11: Definitive Strahlentherapie ....
Kennzahl Nr. 12: Permanente Seedimplantation - D 90 > 130 Gy ....
Kennzahl Nr. 13: HDR-Brachytherapie ....
Kennzahl Nr. 14: Befundbericht Stanzbiopsie (LL QI 1) ....
Kennzahl Nr. 15: Befundbericht Lymphknoten (LL QI 2) ....
Kennzahl Nr. 16: Salvage-Radiotherapie bei rezidiviertem PCa (LL QI 7) ....
Kennzahl Nr. 18: Postoperative Komplikationen nach Radikaler Prostatektomie (LL QI 9) ....
Kennzahl Nr. 19: Komplikationen nach Strahlentherapie (LL QI 10) ....

Quality indicators of the guidelines (LL QI):

In the table of contents and in the respective headings, the indicators which correspond to the quality indicators of the evidence-based guidelines are specifically identified. These quality indicators are based on the strong recommendations of the guidelines and were derived from the guidelines groups in the context of the German Guideline Programme in Oncology (GGPO). Further information: www.leitlinienprogramm-onkologie.de*

The quality indicators (QIs) refer to version 6.2 of the S3 GL on early detection, diagnosis and therapy of the different stages of prostate cancer.

| | Definition of indicator | All clinical sites 2018 | | |
		Median	Range	Patients Total
Numerator	All patients presented in the pre-therapeutic conference	126*	41 – 2,510	22,869
Denominator	All patients who presented themselves to the health care providers I (urology/ radiotherapy) (e.g. via referral) and have been diagnosed as primary cases in line with EB 1.2.1 (without primary M1)	129*	43 – 2,574	23,482
Rate	Target value ≥ 95%	98.76%	83.05% - 100%	97.39% **

Basic data indicator:

The definition of the **numerator**, **denominator** and the **target value** are taken from the data sheet.

The **median** for numerator and denominator does not refer to an existing centre but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.

Range specifies the value range for the numerator, denominator and ratio of all centres.

The column **Patients Total** displays the total of all patients treated according to the indicator and the corresponding quota.

Diagram:

The x-axis indicates the number of centres and the y-axis represents the values in percent or number (e.g. primary cases). The target value is depicted as a green horizontal line. The median, which is also depicted as a green horizontal line, divides the entire group into two equal halves.

General information

DKG
GERMAN CANCER SOCIETY
Certification

	2015	2016	2017	2018	2019
● Max	100%	100%	100%	100%	100%
95. Perzentil	100%	100%	100%	100%	100%
75. Perzentil	100%	100%	100%	100%	100%
Median	97,98%	98,19%	99,00%	98,76%	98,50%
25. Perzentil	95,95%	96,38%	95,63%	96,71%	96,07%
5. Perzentil	83,90%	90,42%	90,10%	92,42%	88,53%
● Min	56,63%	74,66%	43,33%	83,05%	49,11%

Cohort development:

The cohort development in the years **2017, 2018, 2019, 2020** and **2021** is presented in a box plot diagram. This chart provides the distribution overview of each cohort's indicator year and direct comparison to the previous year.

Boxplot:

A box plot consists of a **box with median**, **whiskers** and **outliers**. 50 percent of the centres are within the box. The median divides the entire available cohort into two halves with an equal number of centres. The whiskers and the box cover 90% of the centres. The extreme values are depicted here as dots.

Maximalwe = Maximum value
Antenna = Antenne
Minamalwert = Minimum value

4

Status of the certification system: Prostate Cancer Centres 2022

	31.12.2022	31.12.2021	31.12.2020	31.12.2019	31.12.2018	31.12.2017
Ongoing certification procedures	5	11	22	6	3	9
Certfied centres	156	146	131	127	122	112
Certified clinical sites	157	147	132	128	123	113

Clincial sites taken into account

	31.12.2022	31.12.2021	31.12.2020	31.12.2019	31.12.2018	31.12.2017
Clinical sites included in the Annual Report	145	132	124	122	115	106
Equivalent to	92.3%	89.8%	93.9%	95.3%	93.5%	93.8%
Primary cases total*	36,135	30,336	30,528	29,344	27,160	23,677
Primary cases per centre (mean)*	249,2	229,8	246	241	236	223
Primary cases per centre (median)*	180	171,5	171	170	165	165

*The figures are based on the clinical sites listed in the Annual Report.

This Annual Report looks at the Prostate Cancer Centres certified in the Certification System of the German Cancer Society. The basis for the diagrams in the Annual Report is the Data Sheet.

The Annual Report includes 145 of the 157 certified centre sites. Excluded are 5 sites that were certified for the first time in 2022 (data mapping of complete calendar year not mandatory for inital certifications). Another 5 clinicl sites were unable to submit a final data sheet by the data cutoff date of 31.01.2023. One clinical sites has suspended the certificate in the 1st quarter of 2023, another clinical site will suspend the certificate in the 2nd quarter of 2023. In 2022, therefore, no audit was carried out for the two clinical sites and no Data Sheet was submitted.
A total of 38,445 primary cases of prostate cancer were treated at 155 clinical sites with available Data Sheets. A current overview of all certified sites is shown at www.oncomap.de.

The indicators published here refer to the indicator year 2021. They are the basis for the audits conducted in 2022.

Tumour documentation systems used in Prostate Cancer Centres

DKG
GERMAN CANCER SOCIETY
Certification

- Andere: 11 (7.59%)
- GTDS: 29 (20.00%)
- CREDOS: 8 (5.52%)
- Tudok (Tumorzentrum Regensburg): 4 (2.76%)
- ORBIS-ODOK: 13 (8.97%)
- Ondis: 10 (6.90%)
- ONKOSTAR: 20 (13.79%)
- ODSeasy / ODSeasy Net: 33 (22.76%)
- c37.CancerCenter: 17 (11.72%)

Andere = other
KIS-Erweiterung = KIS enlargement
Tumorzentrum = tumour entre

Legende:	
Andere („others")	System used in ≤ 3 clinical sites

The details on the tumour documentation system was taken from the Data Sheet (Basic Data Sheet). It is not possible to use more than one system. In many cases, support is provided by the cancer registries or there may be a direct link to the cancer registry via a specific tumor documentation system.

Basic data – Primary cases prostate cancer (PCa)

Total primary cases

Pie chart data:
- Locally confined (T1/2-NO-MO – intermediate risk 14,694; 40.66%
- Locally confined (T1/2-NO-MO – high risk 9,203; 25.47%
- Locally confined (1/2-NO-MO – low risk 5,835; 16.15%
- not classified −1,256; 3.48%
- Advanced (N0/1, M1) 2,461; 6.81%
- Advanced (N1, MO) 808; 2.24%
- Locally advanced (T3/4-NO-MO) 1,878; 5.20%

	Total primary cases
Locally confined (T1/2, N0, M0), Low risk	5,835 (16.15%)
Locally confined (T1/2, N0, M0), Intermediate risk	14,694 (40.66%)
Locally confined (T1/2, N0, M0), High risk	9,203 (25.47%)
Locally advanced (T3/4, N0, M0)	1,878 (5.20%)
Advanced (N1, M0)	808 (2.24%)
Advanced (N0/1, M1)	2,461 (6.81%)
Not classified [1]	1,256 (3.48%)
Total primary cases	36,135

1) Not classified-: Nx, Mx, incidental findings after radical cystoprostatectomy (CPE)

Basic data – Distribution non-interventional / interventional primary cases prostate cancer

DKG
GERMAN CANCER SOCIETY
Certification

Non-interventional / interventional primary cases

	Non interventional[1]	Interventional	Total
Locally confined (T1/2, N0, M0), Low risk	2,180 (37.36%)	3,655 (62.64%)	5,835 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	827 (5.63%)	13,867 (94.37%)	14,694 (100%)
Locally confined (T1/2, N0, M0), High risk	223 (2.42%)	8,980 (97.58%)	9,203 (100%)
Locally advanced (T3/4, N0, M0)	26 (1.38%)	1,852 (98.62%)	1,878 (100%)
Advanced (N1, M0)	4 (0.50%)	804 (99.50%)	808 (100%)
Advanced (N0/1, M1)	20 (0.81%)	2,441 (99.19%)	2,461 (100%)
Not classified [2]	148 (11.78%)	1,108 (88.22%)	1,256 (100%)
Total primary cases	3,428	32,707	36,135

[1]   Non-interventional: active surveillance or watchful waiting; histological evidence of prostate cancer mandatory
[2]   Not classified : Nx, Mx, incidental findings after radical cystoprostatectomy

9

Basic data - Distribution of therapies prostate cancer

Non-interventional primary cases (locally confined) – Distribution of therapies

	Non-interventional[1]		Total
	Active-Surveillance[1]	Watchful Waiting[1]	
Locally confined (T1/2, N0, M0), Low risk	1,868 (85.69%)	312 (14.31%)	2,180 (100%)
Locally confined (T1/2, N0, M0), Intermediate risk	522 (63.12%)	305 (36.88%)	827 (100%)
Locally confined (T1/2, N0, M0), High risk	83 (37.22%)	140 (62.78%)	223 (100%)
Total primary cases (locally confined), non-interventional treatment	2,473	757	3,230

[1] Non-interventional: active surveillance or watchful waiting; histological evidence of prostate cancer mandatory

Basic data - Distribution of therapies prostate cancer

Primary cases - Distribution of therapies

	Non-interventional (Active surveillance, Watchful waiting)	Interventional - local treatment of the prostate[1]	Interventional - exclusive systemic treatment	Interventional - other non-local treatment[2]	Total
Locally confined (T1/2, N0, M0), Low risk	2,180 (37.36%)	3,625 (62.13%)	14 (0.24%)	16 (0.27%)	5,835 (100%)
Locally confinded (T1/2, N0, M0), Intermediate risk	827 (5.63%)	13,669 (93.02%)	107 (0.73%)	91 (0.62%)	14,694 (100%)
Locally confinded (T1/2, N0, M0), High risk	223 (2.42%)	8,408 (91.36%)	369 (4.01%)	203 (2.21%)	9,203 (100%)
Locally advanced (T3/4, N0, M0)	26 (1.38%)	1,682 (89.56%)	121 (6.44%)	49 (2.61%)	1,878 (100%)
Advanced (N1, M0)	4 (0.50%)	665 (82.30%)	101 (12.50%)	38 (4.70%)	808 (100%)
Advanced (N0/1, M1)	20 (0.81%)	410 (16.66%)	1,456 (59.16%)	575 (23.36%)	2,461 (100%)
Not classified [2]	148 (11.78%)	1,045 (83.20%)	45 (3.58%)	18 (1.43%)	1,256 (100%)
Total primary cases	3,428	29,504	2,213	990	36,135

1) Interventional - local treatment of the prostate: e.g. radical prostatectomy (RP), radical cystoprostatectomy (CPE), definitive percutaneous radiation, brachytherapy,
2) Interventional - other non-local treatment: e.g. palliative radiation of bone metastases, best supportive care.
3) Not classfied: Nx, Mx, incidental findings after radical cystoprostatectomy (CPE).

Basic data – Primary case distribution in the indicator years 2017 - 2021

Basic data – Distribution of interventional local therapies prostate carcinoma

DKG
GERMAN CANCER SOCIETY
Certification

Interventional primary cases treated - Distribution of therapies

Category	PE	CPE	Incidental finding	Definitive radiotherapy	LDR / HDR / Other
Locally confined (T1/2, N0, M0), low risk	80.72%	0.39%		16.97%	1.93%
Locally confined (T1/2, N0, M0), intermediate	79.43%	0.18%		19.57%	0.82%
Locally confined (T1/2, N0, M0), high risk	75.99%	0.46%		23.00%	0.55%
Locally advamced (T3/4. N0. M0)	67.72%	1.25%		30.80%	0.24%
Advanced (N1, M0)	52.79%	2.26%		44.81%	0.15%
Advanced (N0/1, M1)	45.37%	2.68%		50.73%	1.22%
Not classified	8.33%	5.26%	79.52%		6.12% / 0.77%

(x-axis: 0% to 100% in 10% increments)

	PE [1]	CPE [2] due to PCa	Incidental finding after CPE [2]	Interventional – local treatment of prostata				Total
				Definitive percutaneous radiotherappy	LDR brachytherapy	HDR brachytherapy	Other local therapy[3]	
Locally confined (T1/2, N0, M0) Low risk	2,926 (80.72%)	14 (0.39%)	0 (0.00%)	489 (13.49%)	115 (3.17%)	11 (0.30%)	70 (1.93%)	3,625 (100%)
Locally confinded (T1/2, N0, M0) Intermediate risk	10,857 (79.43%)	25 (0.18%)	0 (0.00%)	2,563 (18.75%)	58 (0.42)	54 (0.40%)	112 (0.82%)	13,669 (100%)
Locally confinded(T1/2, N0, M0) High risk	6,389 (75.99%)	39 (0.46%)	0 (0.00%)	1,867 (22.21%)	6 (0.07%)	61 (0.73%)	46 (0.55%)	8,408 (100%)
Locally advanced (T3/4, N0, M0)	1,139 (67.72%)	21 (1.25%)	0 (0.00%)	510 (30.32%)	0 (0.00%)	8 (0.48%)	4 (0.24%)	1,682 (100%)
Advanced (N1, M0)	351 (52.78%)	15 (2.26%)	0 (0.00%)	298 (44.81%)	0 (0.00%)	0 (0.00%)	1 (0.15%)	665 (100%)
Advanced (N0/1, M1)	186 (45.37%)	11 (2.68%)	0 (0.00%)	207 (50.49%)	0 (0.00%)	1 (0.24%)	5 (1.22%)	410 (100%)
Not classified [3]	87 (8.33%)	55 (5.26%)	831 (79.52%)	56 (5.36%)	5 (0.48%)	3 (0.29%)	8 (0.77%)	1,045 (100%)
Total primary cases	21,935	180	831	5,990	184	138	246	29,504

1) Radical Prostatectomy (PE)

2) Radical cystoprostatectomy (CPE)

3) Other therapies: i.e. HIFU, …

4) Not classified : Nx, Mx, incidential finding after radical cystoprostatectomy (CPE)

Basic data - Distribution of therapies of prostate cancer patients with recurrence and metastasis

DKG
GERMAN CANCER SOCIETY
Certification

Newly diagnosed recurrence – distribution of therapies

other local therapy;
41; 1.27%

HDR-Brachytherapy;
14; 0.43%

exclusive systemic
treatment; 360;
11.11%

other treatment; 1,306;
40.72%

Definitive
percutaneous
radiotherapy; 1,452;
44.83%

Watchful Waiting;
65; 2.01%

PE; 96;
2.96%

CPE due to Pca; 16;
0.43%

Newly diagnosed remote metastasis – distribution of therapies

exclusive systemic
treatment; 525; 29.46%

other treatment; 1.254;
70.37%

Watchful Waiting;
3; 0.17%

|	Active-Surveillance	Watchful Waiting	PE [1]	CPE [2] due to Pca	Incidential finding after CPE	Definitive percuaneous radiotherapy	LDR-Brachy-Therapy	HDR-Brachy-Therapy	other local Therapie [3]	Exclusive systemic therapy	Other therapy [4]	Total
Pat. with newly diagnosed recurrence	0 (0.00%)	65 (2.01%)	96 (2.96%)	16 (0.49%)	0 (0.00%)	1,452 (44.83%)	0 (0.00%)	14 (0.43%)	41 (1.27%)	360 (11.11%)	1,195 (36.89%)	3,239 (100%)
Pat. with newly diagnosed remote metastasis	0 (0.00%)	3 (0.17%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	0 (0.00%)	525 (29.46%)	1,254 (70.37%)	1,782 (100%)

1) Radical Prostatectomy (PE)

2) Radical Cystoprostatectomy (CPE)

3) Other therapies: i.e. HIFU, …

4) Not classified: Nx, Mx, incidential finding after radical cystoprostatectomy

14

1a. Number of primary cases of prostate cancer

Number

Median 171.50
Median 180,00
Sollvorgabe ≥ 100

146 clinical sites

Sollvorgabe = target value

	Definition of indicator	**All clinical sites 2021**		
		Median	**Range**	**Patients total**
Number	Primary cases	180	89 - 2711	36135
	Target value ≥ 100			

		2017	**2018**	**2019**	**2020**	**2021**
•	Max	2626,00	2668,00	2768,00	2660,00	2711,00
	95th percentile	454,60	463,70	451,50	502,55	522,40
	75th percentile	254,50	264,50	274,00	244,25	277,00
	Median	165,00	170,00	171,00	171,50	180,00
	25th percentile	134,50	136,25	143,75	131,75	141,00
	5th percentile	112,10	109,05	114,00	107,00	110,80
•	Min	89,00	102,00	101,00	86,00	89,00

Clinical sites with evaluable data		**Clinical sites meeting the target value**	
Number	%	Number	%
145	100.00%	144	99.31%

Comment:
The number of primary cases has increased disproportionately (+19.1%) compared to the number of certified clinical sites (+9.8%). After a decline in primary cases of 2.8% in the first year of the Covid pandemic in the centres that have been certified since at least 2018, they now show an increase of 5.3%. One centre fell short of the target value in the indicator year, but met it in the 3-year average and, under the Covid special scheme, received a full certificate extension. Based on the current incidence from 2019 (www.krebsdaten.de), the coverage of primary cases treated in the German centres is 49.3%.

15

1b1. Distribution of primary cases with locally confined prostate cancer and low risk

Number

Median 29,00

145 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients total**
Number	Primary cases with locally confined PCa and low risk (PSA ≤ 10ng/ml and cT category ≤ 2a)	29	2 - 403	5835
	No target value			

		2017	**2018**	**2019**	**2020**	**2021**
●	95th percentile	446,00	439,00	423,00	425,00	403,00
	75th percentile	84,00	87,90	81,85	82,90	84,00
	Median	44,00	45,00	44,50	44,00	49,00
	25th percentile	31,00	28,50	32,00	29,00	29,00
	5th percentile	21,00	22,00	20,00	18,00	19,00
	Max	10,40	12,00	11,00	10,00	9,20
●	95th percentile	7,00	7,00	5,00	5,00	2,00

Clinical sites with evaluable data		Clinical sites meeting the target	
Number	%	Number	%
145	100.00%	-----	-----

Comment

In 29,732 patients, the cancer was diagnosed in the localised stage (T1/2 N0 M0). The share of low-risk tumours in localised cancers shows an overall downward trend: After more than 30% were assigned to this group in 2012, the proportion of low-risk cancers has levelled off at 20% in the last 3 years. Overall, the proportion of localised tumours has also decreased since 2012 from 86.7% to 82.3%, but is currently at the level of the last 3 previous years [82.7% - 83.4%].

1b2. Distribution of primary cases with locally confined prostate cancer and intermediate risk

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Number	Primary cases with locally confined PCa and intermediate risk (PSA > 10-20 ng/ml or Gleason-Score 7 or cT 2b)	67	15 - 1571	14694
	No target value			

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	1459,00	1581,00	1615,00	1557,00	1571,00
	95th percentile	169,70	199,10	189,00	194,65	218,00
	75th percentile	87,50	90,75	96,25	94,25	107,00
	Median	54,00	60,00	64,50	60,00	67,00
	25th percentile	38,50	41,25	47,75	45,50	47,00
	5th percentile	23,70	31,00	26,15	25,65	29,00
●	Min	17,00	20,00	10,00	9,00	15,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100,00%	-----	-----

Comment

The number and proportion of primary cases with localised cancer and intermediate risk are increasing: since 2012, the proportion of all primary cases has risen from 35.5% to 40.6%. Within the subgroup of localised cancers, there has also been an increase in the number of tumours with intermediate risk from 40.9% to currently 49.4%.

DKG GERMAN CANCER SOCIETY
Certification

1b3. Distribution of primary cases with locally confined prostate cancer and high risk

145 clinical sites

|	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Number	Primary cases with locally confined PCa and high risk (PSA > 20 ng/ml or Gleason-Score ≥ 8 or cT2c)	45	16 - 654	9203
	No target value			

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	613,00	624,00	660,00	627,00	654,00
	95th percentile	134,50	133,35	147,20	155,70	152,80
	75th percentile	81,00	73,25	71,25	65,25	67,00
	Median	49,00	48,00	50,50	47,50	45,00
	25th percentile	35,00	35,00	38,00	33,00	35,00
	5th percentile	24,00	22,00	26,15	24,10	24,00
●	Min	12,00	14,00	15,00	14,00	16,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100,00%	-----	-----

Comment
After the share of primary cases with high risk in localised cancers grew from 27.8% to 34.3% from 2012 to 2017, it has since shown a downward trend. Currently, 30.9% of localised cancers are assigned to the high-risk group.

DKG
GERMAN CANCER SOCIETY
Certification

1c. Patients with new recurrence and/or distant metastasis

Number

143 clinical sites

|	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Number	Patients with new recurrence and/or distant metastases	27	1 - 137	5021
	No target value			

	2017	2018	2019	2020	2021
● Max	-----	-----	-----	157,00	137,00
95th percentile	-----	-----	-----	101,65	92,90
75th percentile	-----	-----	-----	48,75	50,00
Median	-----	-----	-----	27,50	27,00
25th percentile	-----	-----	-----	15,00	13,50
5th percentile	-----	-----	-----	6,00	4,10
● Min	-----	-----	-----	1,00	1,00

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
130	98.48%	-----	-----

Comments:
The number of patients with new recurrence and/or distant metastases has been systematically recorded since 2020. In addition to the 30,335 primary cases, 5,021 patients with recurrence and/or metachronous metastasis were treated in the centres (previous year 4,587 patients).

2a. Presentation in the weekly pre-therapeutic tumour board – Urology

DKG
GERMAN CANCER SOCIETY
Certification

Sollvorgabe = target value

145 clinical sites

|	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator presented in the pre-therapeutic tumour board	132*	46 - 2528	27597
Denominator	Patients who present to urology or radiotherapy (e.g. via referral) and are diagnosed as primary cases according to CoR 1.2.1 (without primary M1, without incidental findings according to CPE).	135*	46 - 2592	28258
Rate	Target value ≥ 95%	99.07%	79.61% - 100%	97.66%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	99.00%	98.76%	98.50%	98.34%	99.07%
	25th percentile	95.63%	96.71%	96.07%	95.90%	97.08%
	5th percentile	90.10%	92.42%	88.53%	81.01%	92.65%
●	Min	43.33%	83.05%	49.11%	62.03%	79.61%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	133	91.72%

Comment
With very good fulfilment overall, the indicators show an improved implementation of the requirement in the lower percentiles. 62 centres (previous year 44) presented all patients of the denominator in the tumour board. Of the 23 centres that did not achieve the target value in the pre-indicator year, 18 centres currently have a presentation rate of >95%. 12 centres did not meet the target value and justified this, among other things, with incidental findings in cystectomies and TUR-P, direct referral to surgery in the case of external diagnosis, but also staff shortages. In the audits, the auditors formulated one deviation and several critical remarks.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

2b. Presentation in the weekly pre-therapeutic tumour board – Radiotherapy

Sollvorgabe = target value

128 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator presented in the pre-therapeutic tumour board	23*	1 - 104	3388
Denominator	Patients who present to urology or radiotherapy (e.g. via referral) and are diagnosed as primary cases according to CoR 1.2.1 (without primary M1, without incidental findings according to CPE).	24,5*	1 - 105	3497
Rate	Target value ≥ 95%	100%	30.43% - 100%	96.88%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	98.42%	97.69%	100%	99.29%	100%
	5th percentile	83.00%	85.98%	88.81%	80.06%	89.20%
●	Min	40.00%	50.00%	50.00%	30.43%	68.89%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
128	88.28%	116	90.63%

Comment

This indicator also shows a further improvement in the lower percentiles with very good implementation overall. More than 90% of the centres (previous year 84.4%) met the target value. Of the 12 centres with presentation rates <95%, 4 centres also failed to meet the target value of indictaor 2a. The most frequent reasons for not presenting were again identified as omissions and coordination difficulties with cooperation partners.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3a. Presentation in the monthly tumour board – Primary cases post-operative

DKG
GERMAN CANCER SOCIETY
Certification

Sollvorgabe = target value

145 cinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients total**
Numerator	Patients of the denominator presented at the tumour board (post-operative: primary cases operated on and pre-therapeutic: primary M1, recurrence/remote metastases).	30*	7 - 796	6934
Denominator	Primary cases > pT3a and/or R1 and/or pN+	31*	7 - 818	6991
Rate	Target value = 100%	100%	75.00% - 100%	99.18%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	100%	100%	100%	100%	100%
	5th percentile	95.15%	91.35%	90.35%	88.13%	95.49%
●	Min	5.26%	80.65%	41.33%	57.14%	75.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	125	86.21%

Comment
More than 99% of all primary cases of the denominator are presented post-operatively in the tumour board. In 86.2% of the centres (previous year 81.8%), all primary cases of the denominator were presented; in 12 centres (8.3%), the target value was not achieved due to the failure to present an individual case, among other things because of post-operative death, but also omissions and documentation deficits. 3 centres referred to restrictions due to the Covid pandemic.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

3b. Presentation in the monthly tumour board – Primary cases primary M1 pre-therapeutic

DKG GERMAN CANCER SOCIETY
Certification

Sollvorgabe = target value

144 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator presented at the tumour board (post-operative: primary cases operated on and pre-therapeutic: primary M1, recurrence/remote metastases).	16*	1 - 58	2493
Denominator	Primary cases with primary M1	16*	1 - 58	2515
Rate	Target value = 100%	100%	80.00% - 100%	99.13%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	100%	100%	100%	100%	100%
	5th percentile	90.84%	87.50%	87.61%	77.52%	94.12%
●	Min	31.58%	71.43%	72.73%	53.13%	80.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
144	99.31%	126	87.50%

Comment
The target of presenting primary cases with primary distant metastasis pre-therapeutically in the tumour board has been fully implemented by 87.5% of the centres; the fulfilment of the indictaor has also improved further in the lower percentiles. 15 out of 18 centres did not reach the target value due to the failure to present a single patient, mostly due to omissions, but also due to lack of patient consent and patient death.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

DKG GERMAN CANCER SOCIETY Certification

3c. Presentation in the monthly tumour board: Patients with new recurrence and/or distant metastases pre-therapeutic

143 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator presented at the tumour board (post-operative: primary cases operated on and pre-therapeutic: primary M1, recurrence/remote metastases).	27*	1 - 136	4858
Denominator	Patients with new recurrence and/or distant metastases (= indicator 1c)	27*	1 - 137	5021
Rate	Target value = 100%	100%	50.00% - 100%	96.75%**

		2017	**2018**	**2019**	**2020**	**2021**
	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	90.11%	93.33%	96.58%	92.86%	96.29%
	5th percentile	53.61%	63.30%	71.82%	60.00%	73.14%
	Min	17.65%	25.00%	0.00%	20.00%	50.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
143	98.62%	99	69.23%

Comment

The long-term positive development of the indicator continues after a brief dip in the first Corona year. 96.8% (previous year 93.2%) of the patients in the denominator are presented pre-therapeutically, 99 centres (previous year 88) meet the target value. 44 centres did not present all required patients and justified this, among other things, with uncertainty about the obligation to present by further treatment providers, but also omissions and patient deaths.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

4. Active Surveillance (AS)

DKG
GERMAN CANCER SOCIETY
Certification

Begründungspflicht = mandatory statement for reason

145 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases under AS	9*	0 - 67	1868
Denominator	Primary cases with locally confined PCa and low risk(PSA ≤ 10ng/ml and Gleason-Score 6 and cT category ≤ 2a)	29*	2 - 403	5835
Rate	Mandatory statement of reasons*** <0.01%	34.38%	0.00% - 95.24%	32.01%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	83.33%	87.50%	88.89%	91.30%	95.24%
	95th percentile	68.27%	70.12%	69.52%	70.97%	77.71%
	75th percentile	48.71%	42.15%	47.91%	50.00%	50.00%
	Median	27.27%	27.53%	31.42%	31.71%	34.38%
	25th percentile	14.12%	13.43%	11.35%	15.66%	15.38%
	5th percentile	1.02%	1.19%	0.95%	3.22%	0.00%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
145	100.00%	136	93.79%

Comment
The guideline QI shows a positive development at the median and the upper percentiles. On median, 34.4% of the denominator's primary cases are actively monitored. 9 centres did not carry out AS and justified this with the lack of health insurance approval at the site and the patient's wish for definitive therapy.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausiblilty corridor, centres have to give an explanation.

5. Percutaneous radiotherapy with hormone ablation therapy for locally confined PCa with high risk (GL QI)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Median 82,69%

Sollvorgabe ≥ 70%

Begründungspflicht = mandatory statement for reason

144 clinical sites

|	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with additional neo- and/or adjuvant hormone ablative therapy	9*	0 - 35	1472
Denominator	Primary cases with prostate cancer T1-2 N0 M0 with high risk (PSA >20ng/ml or Gleason-Score ≥ 8 or cT category 2c) and percutaneous radiotherapy	12*	1 - 43	1867
Rate	Target value ≥ 70%	82.69 %	0.00% - 100%	78.84% **

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	95.24%	100%	94.27%	93.94%	94.44%
	Median	80.00%	86.34%	80.00%	84.62%	82.69%
	25th percentile	57.14%	60.00%	62.62%	65.16%	72.22%
	5th percentile	28.00%	26.59%	24.69%	23.64%	39.72%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
144	99.31%	113	78.47%

Comment
In an increasing number of centres, neo- and/or adjuvant hormone ablative therapy is carried out for localised PCa with high risk and percutaneous radiotherapy. After setting a target value (previously requiring a statement of reasons <90%), almost 80% of the centres met the requirement and carried out the required therapy in ≥70% of primary cases. In 34 centres (previous year 29), 100% of the GL-QI was implemented. The two centres in which no hormone ablative therapy was carried out (1 and 6 patients in the denominator) justified this with external further care or refusal by the patient.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

26

6. Psycho-oncological counselling

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Begründungspflicht > 80%

Median 19,15%

Begründungspflicht < 4%

145 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2021		
		Range	**Median**	**Patients Total**
Numerator	Patients of the denominator who received psycho-oncological counselling on an inpatient or outpatient basis (duration of conversation ≥ 25 min.)	41*	1 - 656	8492
Denominator	Primary cases (= indicator 1a) and patients with first manifestation of local recurrence and/or metastases (= indicator 1c)	213*	90 - 2831	41156
Rate	Mandatory statement of reasons*** <4% and >80%	19.15 %	0.47% - 83.80%	20.63%**

		2017	**2018**	**2019**	**2020**	**2021**
	Max	93.94%	84.73%	77.10%	71.43%	83.80%
	95th percentile	60.47%	55.09%	52.15%	55.81%	53.60%
	75th percentile	36.82%	37.00%	35.27%	33.56%	34.76%
	Median	17.51%	21.01%	19.24%	17.25%	19.15%
	25th percentile	8.39%	9.17%	8.94%	8.22%	8.59%
	5th percentile	1.58%	1.79%	2.51%	2.94%	3.11%
	Min	0.70%	0.52%	0.67%	0.94%	0.47%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
145	100,00%	133	91,72%

Comment
The median and average rate has been constant at around 20% for years. 8 of the 11 centres with a coverage rate <4% (previous year 13) referred to low demand despite screening and treatment offers. Other reasons were restrictions due to the covid pandemic and an identified screening deficit for outpatients under care.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausability corridor, centres have to give an explanation.

27

7. Social service counselling

Rate

Median 53,77%

Begründungspflicht < 50%

145 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator who received counselling from the social service on an inpatient or outpatient basis	100*	1 - 1618	21183
Denominator	Primary cases (= indicator 1a) and patients with new recurrence and/or distant metastases (= indicator 1c)	213*	90 - 2831	41156
Rate	Mandatory statement of reasons*** <50%	53.77%	0.37% - 92.61%	51.47%**

	2017	2018	2019	2020	2021
Max	89.87%	88.22%	91.22%	91.87%	92.61%
95th percentile	75.22%	74.96%	77.00%	75.69%	75.16%
75th percentile	60.42%	60.25%	60.45%	60.00%	64.02%
Median	50.75%	51.04%	51.56%	50.61%	53.77%
25th percentile	35.94%	39.65%	39.66%	36.68%	39.65%
5th percentile	5.36%	3.43%	4.65%	2.88%	2.45%
Min	0.40%	0.39%	0.00%	0.37%	0.37%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
145	100.00%	90	62.07%

Comment
The indicator shows better implementation in the second Corona year. Both the overall rate, the median and the proportion of centres in the plausibility corridor have increased compared to the previous year. Of the 59 centres with a rate below the lower plausibility threshold in 2020, 34 have a better rate (median + 3.2 percentage points). 17 centres with a rate <50% are located abroad, where other legal regulations and responsibilities apply.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

8. Patients enrolled in a study

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Median 38,39%

Sollvorgabe ≥ 5%

25   50   75   100   125

145 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients enrolled in a study with an ethics vote	66*	1 - 2282	16033
Denominator	Primary cases (= indicator 1a)	180*	89 - 2711	36135
Rate	Target value ≥5%	38.39%	0.88% - 153.45%	44.37%**

		2017	**2018**	**2019**	**2020**	**2021**
	Max	190.94%	449.77%	345.43%	242.61%	153.45%
	95th percentile	65.54%	82.22%	105.88%	90.12%	80.80%
	75th percentile	38.07%	43.35%	52.99%	55.16%	52.35%
	Median	17.25%	26.39%	39.09%	39.36%	38.39%
	25th percentile	7.24%	13.36%	23.24%	24.31%	25.58%
	5th percentile	0.62%	5.46%	7.41%	7.14%	10.47%
	Min	0.00%	0.00%	0.00%	0.00%	0.88%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	144	99.31%

Comment
The study rate has remained almost unchanged in recent years. However, due to a decline in the maximum, the overall rate has decreased slightly (previous year 50.9%). 1 centre did not meet the target value of ≥5% (previous year 4), but already included several patients in studies in the following year and acquired further studies.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

DKG GERMAN CANCER SOCIETY
Certification

9. Number of prostatectomies – Centre

Number

Median 97,00, Sollvorgabe ≥ 50

Sollvorgabe = target value

145 clinical sites

|	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Number	Radical prostatectomies / total cystoprostatectomies (see Basic Data)	97	34 - 2565	23058
	Target value ≥ 50			

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	2387,00	2498,00	2642,00	2549,00	2565,00
	95th percentile	372,30	368,50	372,90	390,90	420,00
	75th percentile	151,00	156,00	166,50	146,75	163,00
	Median	76,00	81,00	84,00	84,50	97,00
	25th percentile	56,00	59,50	60,75	59,00	61,00
	5th percentile	34,00	42,00	40,75	38,55	42,20
●	Min	26,00	26,00	27,00	19,00	34,00

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	124	85.52%

Comment:
Compared to the previous year, the number of prostatectomies has increased significantly across the entire range and is above the level of the pre-Covid era. 80.6% of all prostatectomies in Germany (27,619, source destatis) were performed in certified centres. Nevertheless, 21 centres did not meet the target value of ≥50 PE. Of these, 11 centres received a certificate extension in the re-audit (once limited to 1 year) with a sufficient number of primary cases (>100) and a recommendation to maintain the certificate in the audit report; 10 centres were in the surveillance audit, so that the shortfall had no effect on the certificate.

DKG GERMAN CANCER SOCIETY
Certification

10. Recording of R1 resections for pT2 c/pN0 or Nx M0

Rate

Sollvorgabe ≤ 15%

Median 9,09%

145 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Surgeries of the denominator with R1	5*	0 - 100	1078
Denominator	Surgeries on primary cases with pT2 c/pN0 or Nx M0	58*	16 - 1381	12783
Rate	Target value ≤ 15%	9.09%	0,00% - 31.43%	8.43%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	50.00%	45.00%	29.27%	38.71%	31.43%
	95th percentile	25.00%	20.17%	19.97%	22.07%	19.77%
	75th percentile	12.50%	11.94%	13.57%	13.82%	14.29%
	Median	8.97%	8.66%	9.54%	9.81%	9.09%
	25th percentile	5.56%	5.18%	5.37%	5.72%	4.21%
	5th percentile	0.00%	0.00%	0.00%	0.00%	0.11%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	119	82.07%

**Comment**
At 9.1% (median) and 8.4% (overall rate), the proportion of R1 resections is slightly below the level of the previous year. Of the 24 centres with a rate above the target in the previous year, 21 centres were able to reduce the R1 resection rate by a median of 6.4 percentage points; 10 centres again had R1 resection rates >15%. In the case of predominantly multifocal R1 and incision margins >3mm, 4 centres received a certificate with reduced period; deviations were pronounced in 2 surveillance audits. Several centres have worked on the rate in quality circles and planned / initiated measures (large-area frozen section, frozen section examination of defined resection margins).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

11. Definitive radiotherapy

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Begründungspflicht > 90%

90%
80%
70%
60%
50%
40%
30%
20%
Median 18,80%
10%
Begründungspflicht < 10%
0

25   50   75   100   125

145 clinical sites

Begründungspflicht = mandatory statement for reason

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with definitive radiotherapy	39*	1 - 182	5990
Denominator	Primary cases (= indicator 1a)	180*	89 - 2711	36135
Rate	Mandatory statement of reasons*** <10% and >90%	18.80%	0.06% - 58.79%	16.58%**

*

		2017	2018	2019	2020	2021
●	Max	41.67%	52.20%	52.45%	61.26%	58.79%
	95th percentile	38.81%	39.02%	42.23%	41.40%	44.24%
	75th percentile	26.44%	28.33%	30.09%	29.02%	27.08%
	Median	18.39%	18.11%	18.75%	18.56%	18.80%
	25th percentile	11.42%	12.42%	11.16%	12.18%	10.64%
	5th percentile	3.97%	4.88%	2.81%	3.48%	3.33%
●	Min	0.41%	0.06%	0.13%	1.00%	0.06%

| Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
145	100.00%	112	77.24%

Comment
With a slight increase in the median, the overall rate has declined slightly for the first time in 3 years. The proportion of centres requiring a statement of reasons also increased from 17.4% to 22.8%. The centres with rates <10% justified this in particular with an explicit patient decision against radiotherapy (9x), supraregional catchment area for surgery (5x), as well as radiotherapy close to home (2x).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausablilty corridor, centres have to give an explanation.

32

12. Permanent seed implantation - D 90 > 130 Gy

Rate

Median 100,00%

Sollvorgabe ≥ 90%

17 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator in which D90 > 130 Gy was achieved	6*	1 - 33	179
Denominator	Primary cases with LDR mono-therapy	6*	1 - 33	186
Rate	Target value ≥ 90%	100%	66.67% - 100%	96,.4%**

		2017	2018	2019	2020	2021
●	Max	-----	-----	100%	100%	100%
	95th percentile	-----	-----	100%	100%	100%
	75th percentile	-----	-----	100%	100%	100%
	Median	-----	-----	100%	100%	100%
	25th percentile	-----	-----	100%	99.31%	100%
	5th percentile	-----	-----	93.75%	67.86%	66.67%
●	Min	-----	-----	79.49%	0.00%	66.67%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
17	11.72%	14	82.35%

Comment:
Permanent seed implantation took place in 17 centres in the indictaor year 2021 (2020: 20 centres). As in the previous year, 3 centres did not reach the target value of 90%. The centres referred to therapy discontinuations by patients and differences between therapy planning and control due to different imaging techniques.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

13. HDR brachytherapy

145 clinical sites

	Definition of indicator	**All clinical sites 2021**		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with HDR brachytherapy	0*	0 - 25	138
Denominator	Primary cases (= indicator 1a)	180*	89 - 2711	36135
Rate	No target value	0.00%	0.00% - 15.63%	0.38%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	16.67%	14.57%	15.97%	21.43%	15.63%
	95th percentile	4.20%	6.52%	5.30%	3.79%	1.90%
	75th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
	Median	0.00%	0.00%	0.00%	0.00%	0.00%
	25th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
	5th percentile	0.00%	0.00%	0.00%	0.00%	0.00%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

| **Clinical sites with evaluable data**		**Clinical sites meeting the target value**	
Number	%	Number	%
145	100,00%	-----	-----

Comment
The absolute number of HDR brachytherapies has been decreasing continuously since 2019. In 18 centres (previous year 17), a total of 138 primary cases (previous year 164) were treated; in 10 centres, the proportion of HDR therapies decreased, and in 2 centres where this therapy was performed in the previous year, no HDR was performed in 2021.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

14. Diagnostic report – Punch biopsy (GL QI)

DKG
GERMAN CANCER SOCIETY
Certification

145 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with complete diagnostic report	136*	13 - 1650	26611
Denominator	Primary cases with punch biopsy	149*	13 - 2684	30653
Rate	Target value ≥ 80%	97.05%	27.83% - 100%	86.81%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	97.86%	98.06%	99.56%	99.71%	99.57%
	Median	88.16%	92.95%	94.62%	96.82%	97.05%
	25th percentile	70.42%	80.04%	84.92%	86.00%	88.89%
	5th percentile	45.74%	48.10%	55.83%	53.00%	80.62%
●	Min	3.60%	30.04%	18.73%	0.90%	27.83%

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	138	95.17%

Comment
The quality indicator of the guideline shows a sustained positive development across the board. 7 centres with complete findings in <80% of primary cases justified this with externally performed and reviewed punch biopsies (6x), in which no semi-quantitative estimation of the tumour extent was available. One centre pointed to a significantly better implementation of the indicators after initial certification.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator..

35

15. Diagnostic report – Lymph nodes (GL QI)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Median 100,00%

Sollvorgabe ≥ 80%

145 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with diagnostic reports stating: • pN category • number of affected lymph nodes in relation to resected lymph nodes	87*	16 - 1863	20016
Denominator	Primary cases with lymphadenectomy	88*	16 - 1864	20272
Rate	Target value ≥ 80%	100%	82.71% - 100%	98.74%**

*

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	100%	100%	100%	100%	100%
	25th percentile	97.89%	98.17%	98.50%	98.79%	98.91%
	5th percentile	89.03%	88.17%	91.79%	93.12%	94.65%
●	Min	27.14%	32.61%	68.18%	60.87%	82.71%

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100,00%	145	100,00%

Comment
The QI for completeness of findings in primary cases with lymphadenectomy is also developing positively. Whereas in the previous year 3 centres were able to present complete diagnostic reports in less than 80% of lymphadenectomies, after the introduction of a target value all centres fulfilled this requirement.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

DKG GERMAN CANCER SOCIETY
Certification

16. Begin salvage-radiotherapy (SRT) for recurrent prostate cancer (GL QI)

Rate

Median 82,71%

Sollvorgabe ≥ 70%

25   50   75   100   125

Sollvorgabe = target value

138 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator with beginning SRT and PSA <0.5 ng/ml	6*	0 - 298	1538
Denominator	Patients after PE and PSA recurrence and SRT	7*	1 - 363	1974
Rate	Target value ≥ 70%	82.71%	0.00% - 100%	77.91%**

		2017	2018	2019	2020	2021
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	98.08%	100%	100%
	Median	80.00%	78.16%	80.00%	81.82%	82.71%
	25th percentile	71.83%	67.50%	67.28%	72.73%	70.98%
	5th percentile	36.85%	37.75%	39.63%	37.45%	39.00%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
138	95.17%	109	78.99%

Comment
The guideline QI is almost unchanged compared to the previous year. 29 centres (previous year 28) did not meet the target value and attributed this to the late allocation (PSA ≥0.5) of external medical staff. The centres want to counteract this through continuing education and direct discussions. In individual cases, the centres also cited delayed therapies by patients.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

18. Postoperative complications after radical prostatectomy (GL QI)

DKG GERMAN CANCER SOCIETY
Certification

Rate

Sollvorgabe ≤ 15%

Median 3,95%

143 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**PatientsTotal**
Numerator	Primary cases of the denominator with complications Clavien-Dindo grade III or IV within the first 6 months after radical prostatectomy	2*	0 - 70	563
Denominator	Primary T1-2 N0 M0 and radical prostatectomy (from the previous indicator year)	52*	12 - 1485	12605
Rate	Target value ≥ 15%	3.95%	0.00% - 20.00%	4.47%**

		2017	2018	2019	2020	2021
●	Max	-----	-----	-----	-----	20.00%
	95th percentile	-----	-----	-----	-----	13.61%
	75th percentile	-----	-----	-----	-----	8.33%
	Median	-----	-----	-----	-----	3.95%
	25th percentile	-----	-----	-----	-----	0.47%
	5th percentile	-----	-----	-----	-----	0.00%
●	Min	-----	-----	-----	-----	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
143	98.62%	140	97.90%

Comment
The denominator of the indictaor has been modified and now only includes primary cases with histologically confirmed T1-2 category. After the introduction of a target value (previously requiring a statement of reasons >30%), 3 centres have complication rates >15%. The most frequent reasons for complications requiring revision were lymphoceles. The centres expect an improvement in their complication rates after the change in surgical techniques (flattening of the learning curve, peritoneal fenestration, introduction of surgical robots).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

19. Complications after radiotherapy (GL QI)

Rate

Sollvorgabe ≤ 3%

Median 0,00%

143 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	Range	Patients Total
Numerator	Primary cases of the denominator with complications CTCAE grade III or IV within the first 6 months after radiotherapy	0*	0 - 2	19
Denominator	Primary cases with definitive ratiotherapy (from the previous indicator year)	45*	2 - 120	6476
Rate	Target value ≤ 3%	0.00%	0.00% - 4.88%	0.29%**

		2017	2018	2019	2020	2021
●	Max	-----	5.26%	16.67%	9.09%	4.88%
	95th percentile	-----	3.82%	3.55%	2.73%	1.81%
	75th percentile	-----	0.00%	0.00%	0.00%	0.00%
	Median	-----	0.00%	0.00%	0.00%	0.00%
	25th percentile	-----	0.00%	0.00%	0.00%	0.00%
	5th percentile	-----	0.00%	0.00%	0.00%	0.00%
●	Min	-----	0.00%	0.00%	0.00%	0.00%

Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
143	98.62%	142	99.30%

**Comment**

In a total of 19 primary cases (previous year 27) with definitive radiotherapy, higher-grade AE (CTCAE grade III/IV) were observed after radiotherapy. 1 centre with sufficient fulfillment of the target value in 2020 and with a small denominator did not meet the newly defined target value of ≤3% (previously ≤5%).

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

20. Dental examination prior to commencement of bisphosphonate or denosumab therapy (GL QI)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Median 100,00%
Sollvorgabe ≥ 90%

Sollvorgabe = target value

111 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Patients of the denominator with recommendation of a dental examination before the start of bisphosphonate or denosumab therapy.	3*	0 - 34	537
Denominator	Patients with bisphosphonate or denosumab therapy	3*	1 - 36	565
Rate	Target value ≤ 90%	100%	0.00% - 100%	95.04%**

		2017	2018	2019	2020	2021
●	Max	100%	100%	100%	100%	100%
	95th percentile	100%	100%	100%	100%	100%
	75th percentile	100%	100%	100%	100%	100%
	Median	30.00%	100%	100%	100%	100%
	25th percentile	1.53%	50.00%	50.00%	60.00%	100%
	5th percentile	0.31%	0.00%	0.00%	0.00%	50.00%
●	Min	0.00%	0.00%	0.00%	0.00%	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
111	76.55%	97	87.39%

Comment
The proportion of patients with a recommendation for dental examination has increased significantly to 95.0% (previous year 56.4%). After the introduction of a target value, this is fulfilled by 87.4% of the centres. 14 centres made a recommendation in <90% of index patients and justified this with the initiation of therapy by other therapists (6x). In individual cases, it was unclear whether a recommendation was made due to documentation deficits. The auditors remarked that even patients with full dentures should be examined by a dentist.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

40

21. No hormone ablation therapy for locally advanced PCa with radical PE (GL QI)

DKG GERMAN CANCER SOCIETY
Certification

Rate

Median 0,00%, Sollvorgabe < 0,1%

145 clinical sites

Sollvorgabe = target value

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patients Total**
Numerator	Primary cases of the denominator with adjuvant hormone ablation therapy	0*	0 - 9	66
Denominator	Primary cases with PCa T3-4 N0 M0 and PE	24*	4 - 646	6048
Rate	Target value < 0.1%	0.00%	0.00% - 25.00%	1.09%**

		2017	**2018**	**2019**	**2020**	**2021**
●	Max	-----	-----	50.00%	30.00%	25.00%
	95th percentile	-----	-----	13.83%	11.40%	9.43%
	75th percentile	-----	-----	1.77%	0.00%	0.00%
	Median	-----	-----	0.00%	0.00%	0.00%
	25th percentile	-----	-----	0.00%	0.00%	0.00%
	5th percentile	-----	-----	0.00%	0.00%	0.00%
●	Min	-----	-----	0.00%	0.00%	0.00%

| Clinical sites with evaluable data		Clinical sites meeting the target value	
Number	%	Number	%
145	100.00%	120	82.76%

Comment
The GL-QI continues to show a positive development and better implementation by the centres. In 25 centres (previous year 30), adjuvant hormone therapy was carried out in primary cases with locally advanced PCa. PCa were treated with adjuvant hormone therapy. Most frequently, the centres carried out ADT (Androgen Deprivation Therapy) due to an R1 resection (6x) and abnormal PSA values (5x). Other reasons were study participation (3x) and young age (2x). The centres remarked that ADT was partly initiated by further therapists.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.

22. Focal therapy for locally advanced prostate cancer (GL QI)

DKG
GERMAN CANCER SOCIETY
Certification

Rate

Begründungspflicht > 0,01% Median 0,00%

Begründungspflicht = mandatory statement for reason

139 clinical sites

	Definition of indicator	All clinical sites 2021		
		Median	**Range**	**Patienten Gesamt**
Numerator	Primary cases of the denominator who received focal therapy	0*	0 - 1	2
Denominator	Primary cases with locally advanced prostate cancer	8*	1 - 205	1878
Rate	Mandatory statement of reasons*** >0,01%	0.00%	0.00% - 11.11%	0.11%**

		2017	**2018**	**2019**	**2020**	**2021**
	Max	-----	-----	-----	-----	11.11%
	95th percentile	-----	-----	-----	-----	0.00%
	75th percentile	-----	-----	-----	-----	0.00%
	Median	-----	-----	-----	-----	0.00%
	25th percentile	-----	-----	-----	-----	0.00%
	5th percentile	-----	-----	-----	-----	0.00%
	Min	-----	-----	-----	-----	0.00%

Clinical sites with evaluable data		Clinical sites meeting the plausibility limits	
Number	%	Number	%
139	95.86%	137	98.56%

Comment
The new GL-QI was recorded for the first time in 2021 and is already being implemented very well by the centres. In 2 centres, 1 primary case each with locally advanced cancer received focal therapy, partly at the express request of the patient.

*The median for numerator and denominator does not refer to an existing centre, but reflects the median of all numerators of the cohort and the median of all denominators of the cohort.
** Percentage of total patients treated in centers according to the numerator.
*** If value is outside the plausability corridor, centres have to give an explanation.

WISSEN AUS ERSTER HAND
(FIRST-HAND KNOWLEDGE)

Find out more on www.krebsgesellschaft.de

Authors

German Cancer Society (DKG)
Certification Committee Prostate Cancer Centres
Martin Burchardt, Spokemen Certification Committee
Jan Fichtner, Spokemen Certification Committee
Simone Wesselmann, Deutsche Krebsgesellschaft e.V.
Johannes Rückher, Deutsche Krebsgesellschaft e.V.
Martin Utzig, Deutsche Krebsgesellschaft e.V.
Ellen Griesshammer, Deutsche Krebsgesellschaft e.V.
Nele Grapentin, Deutsche Krebsgesellschaft e.V.
Daniela Miller, OnkoZert
Florina Dudu, OnkoZert